|
|
|
|
Science Sparks @ ACTREC
|
 06 July 2026 |
Vol. No. 15 ; Issue No.742 |
|
|
Publications
|
|
1. Maniar J, Datt P, Dange PP, Kailaje V, Lakhera M, Samarth M, Durve T, Kadam A, Gandhi KA, Gupta S. Microenvironmental cues that regulate cancer cell dormancy in estrogen-receptor positive and triple-negative breast cancer cell lines. Cancer Medicine. 15(7):e72059
2. Terlizzi M, Ploussard G, Fiard G, Murthy V, Ost P, Zilli T, Zamboglou C, Blanchard P, Sargos P. Re-evaluating biochemical recurrence definitions after radiation therapy: Time to move beyond "Phoenix"? International Journal of Radiation Oncology Biology Physics. 125(3):875-877.
3. Kamran S, Mahmood H, Chopra S, Chatterjee S, Ooi KY, Zaid RM, Chitapanarux I, Nuryadi E, Gondhowiardjo S, Kawamura M, Chang JH, Minjgee M, Bayasgalan U, Faheem M, Fatima H. Mapping breast cancer care patterns in FARO member countries: A survey. Journal of Cancer Policy
4. Khanna D, Pentapati SSK, Sharma P, Shruti T, Vishawakarma R, Sharma A, Balasundaram P, Maurya NK, Maurya VK, Varma RK, Budukh A, Mishra G, Pradhan S, Chaturvedi P. Effectiveness of a capacity-building training for knowledge and practices of tobacco control and oral cancer prevention: a pre-post study from rural northern India. BMC Oral Health.
Book Chapter
Pal S, Mhatre S, Sandbhor P. (2026). Nanotechnology-Stem Cell Strategies in 3D Glioblastoma Organoid: Targeting Glioma Stem Cells Within a Complex Tumor Microenvironment. In: Methods in Molecular Biology. Springer, New York.
|
|
|
|
|
Interesting Reads
|
|
Rovers KP, Bakkers C, van den Heuvel TBM, van de Vlasakker VCJ, Kerkhoff TME, Nienhuijs SW, Burger JWA, Creemers GM, van Hellemond IEG, Tuynman JB, Kusters M, Buffart TE, Aalbers AGJ, Kok NFM, Chalabi M, Boerma D, Brandt-Kerkhof ARM, de Reuver PR, Hemmer PHJ, van Grevenstein WMU, van der Speeten K, Snaebjornsson P, Lee-Law PY, Lahaye MJ, Nederend J, Kranenburg O, Bouma JM, Punt CJA, Dijkgraaf MGW, Tanis PJ, de Hingh IHJT; CAIRO6 Investigators; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group (2026). Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial. Lancet Oncology. 27(7):849-863.
|
|
|
Video of the Week
|
|
| Battling Treatment Resistance in Cancer: Root Causes and Strategies to Uproot Them
|
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2020, FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for people with unresectable pleural mesothelioma who have not received other treatments.
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
